US on a steady growth path; sizeable launches lined up in FY23: Cipla continues to see strong traction for its gProventil (albuterol inhaler) launch in the US where it has garnered 13.2% volume share. 4Q US sales at $138 m declined 2% qoq on lack of meaningful launches.
from The Financial Express https://ift.tt/3waTs56
Monday, 17 May 2021
Analyst Corner: Maintain ‘buy’ on Cipla, raise TP to Rs 1,065
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment